Tauriga Sciences Inc. Increases Equity Stake in Colorado Based NASDAQ Listed Biotechnology Firm Focused in the Medical Field of Urology

NEW YORK, NY, March 09, 2018 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has increased its equity stake in a Colorado based NASDAQ Listed Biotechnology Company Firm focused on the medical field of Urology.

On March 2, 2018, the Company disclosed its $70,739.95 investment into AYTU BioScience, Inc. (“AYTU”).  As of today’s date, the Company has increased its aggregate investment into AYTU to $82,269.79; Tauriga now holds exactly 187,311 common shares (at price of $0.439) and 111,111 registered 5-year warrants exercisable at a strike price of 54 cents (these warrants expire on March 5, 2023). 

The Company acquired its above-referenced stake in AYTU through both open market purchase(s) and participation in a $12,000,000 Registered Private Placement Financing with Warrant coverage (“the Placement’).  These 111,111 registered 5-year warrants were acquired through the Company’s participation in the Placement.

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit our corporate website at www.tauriga.com

FORWARD-LOOKING STATEMENTS:

This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events.  These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones.  Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated.  Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission.  Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. 

CONTACT INFORMATION

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY  10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:  [email protected]
cell # (917) 796 9926
www.tauriga.com